Meeting
2017 ASCO Annual Meeting
Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).
Authors
Lauren Hittson
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Lauren Hittson , John Glod , Melissa Amaya , Joanne Derdak , Brigitte C. Widemann , Rosandra N. Kaplan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02390752
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10546)
DOI
10.1200/JCO.2017.35.15_suppl.10546
Abstract #
10546
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
First Author: Brigitte C. Widemann
Poster
2018 ASCO Annual Meeting
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).
First Author: Birgit Geoerger
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang